AI assistant
Telix Pharmaceuticals Ltd — Call Transcript 2021
Feb 15, 2021
31324_rns_2021-02-15_21c1860d-e753-48a0-aa01-25dec9e13fc9.pdf
Call Transcript
Open in viewerOpens in your device viewer
Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia
==> picture [147 x 81] intentionally omitted <==
Telix FY2020 Results and Company Update Conference Call
Melbourne (Australia) – 16[th ] February 2021 . Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) advises it will hold an investor conference call at 8:00am AEDT on Friday 26[th] February 2021 to present the Company’s FY2020 results together with an update on Telix’s operations.
Participants can register for the conference call by navigating to: https://s1.c-conf.com/DiamondPass/10012118-jol076.html
About Telix Pharmaceuticals Limited
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow us on Twitter (@TelixPharma) and LinkedIn.
Telix Corporate Contact
Dr. Christian Behrenbruch Telix Pharmaceuticals Limited Managing Director and CEO Email: [email protected]
Telix Investor Relations
Dr. David N. Cade Telix Pharmaceuticals Limited CBO and Head of Investor Relations Email: [email protected]
Important Information
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.
Page 1